InCephalo is a preclinical stage biotech company with a compartment locked (CLocked) technology. InCephalo is positioning itself as a CLocked Fc-Fusion Cytokine and antibody company. The company’s first asset is a CLocked IL-12Fc for the treatment of glioblastoma.